The Patent Finder
US

Particle Formulations for Use in Pharmaceutical Compositions

US 8,398,967 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended May 29, 2024 · High confidence

USPTO later recorded it as expired for non-payment on Apr 21, 2025.

Filed Apr 21, 2011 as application 13/091,970 · Granted Mar 19, 2013
Base term plus 162 days of patent term adjustment (USPTO delay)
Today
20 years from filing
Term ended May 29, 2024
2003 2026
Clock starts
Dec 19, 2003
Term ended
May 29, 2024
Granted
Mar 19, 2013
base term patent term adjustment after the term ends fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
162
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,731,947, US 7,964,183, to May 29, 2024. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term runs 162 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Dec 19, 2003, when application 10/742,730, the earliest non-provisional in its chain, was filed (this one was filed Apr 21, 2011)Dec 19, 2023High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+162 days, USPTO patent term adjustment recordMay 29, 2024High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,731,947, US 7,964,183)resolves to May 29, 2024, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
USPTO status recordRecorded as expired for non-payment on Apr 21, 2025, after the term endedno changeHigh confidence
Computed term endThe steps above, in orderMay 29, 2024High confidence

This family

Application 10/742,730Abandoned
not computed
not computed
US 7,731,947In force
May 2028
May 2028
Application PCT/US2004/038409PCT application
no patent term
no patent term
Application 12/315,194Abandoned
not computed
not computed
US 7,964,183Term ended
Nov 2024
Nov 2024
US 8,257,691Term ended
Nov 2024
Nov 2024
US 8,398,967this patent
May 2024
May 2024
US 9,724,293Lapsed on the fee record
Aug 2021
Aug 2021
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jul 21, 2011
Reel 26628, frame 839
Eliaz, Rom Ezer; Zhang, Yuanpeng; Rohloff, Catherine Manya; Weeks, Eric William; Junnarkar, GunjanIntarcia Therapeutics, Inc.Assignment of Assignor's Interest
Nov 14, 2012
Reel 29299, frame 678
Intarcia Therapeutics, Inc.U.S. Bank National Association, as Collateral AgentSecurity Agreement
Oct 23, 2015
Reel 36942, frame 544
U.S. Bank National Association, as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Oct 9, 2019
Reel 50673, frame 20
Intarcia Therapeutics, Inc.; Intarcia Ireland LimitedMidcap Financial Trust, As AgentSecurity Interest
Oct 23, 2019
Reel 50801, frame 267
Intarcia Therapeutics, Inc.Baupost Private Investments Bviv-3, L.L.C., as Collateral AgentSecurity Interest
Jan 29, 2020
Reel 51739, frame 453
Baupost Private Investments Bviv-3, L.L.C. as Collateral AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
Reel 52433, frame 1
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.; Intarcia Ireland LimitedRelease of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Therapeutics, Inc.Release of Security Interest
Apr 17, 2020
reel/frame not recorded
Midcap Financial Trust, As AgentIntarcia Ireland LimitedRelease of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited